Vivani Medical (NASDAQ:VANI – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01), Zacks reports.
Vivani Medical Price Performance
NASDAQ:VANI traded down $0.02 on Wednesday, reaching $1.13. The stock had a trading volume of 134,393 shares, compared to its average volume of 318,191. Vivani Medical has a 12-month low of $0.92 and a 12-month high of $1.66. The company has a market cap of $101.93 million, a price-to-earnings ratio of -3.23 and a beta of 2.51. The firm’s fifty day moving average is $1.20 and its two-hundred day moving average is $1.25.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. Wall Street Zen cut Vivani Medical from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $3.75.
Get Our Latest Report on Vivani Medical
About Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence. The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes.
Read More
- Five stocks we like better than Vivani Medical
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
